MA39751B1 - Antibody compositions for the treatment of tumors - Google Patents
Antibody compositions for the treatment of tumorsInfo
- Publication number
- MA39751B1 MA39751B1 MA39751A MA39751A MA39751B1 MA 39751 B1 MA39751 B1 MA 39751B1 MA 39751 A MA39751 A MA 39751A MA 39751 A MA39751 A MA 39751A MA 39751 B1 MA39751 B1 MA 39751B1
- Authority
- MA
- Morocco
- Prior art keywords
- present
- antigen
- binding
- bispecific antibodies
- bispecific
- Prior art date
Links
Landscapes
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
La présente invention concerne des anticorps bispécifiques qui se lient à cd3 et à des antigènes tumoraux et leurs méthodes d'utilisation. Selon certains modes de réalisation, les anticorps bispécifiques selon la présente invention présentent des fonctions effectrices réduites et possèdent un profil de liaison unique par rapport aux récepteurs fc?. Les anticorps bispécifiques sont modifiés pour induire de façon efficace la mort à médiation par les lymphocytes t de cellules tumorales. Selon certains modes de réalisation, la présente invention concerne des molécules de liaison à un antigène bispécifiques comprenant un premier domaine de liaison à un antigène qui se lie spécifiquement au cd3 humain, une seconde molécule de liaison à un antigène qui se lie spécifiquement au cd20 humain, et un domaine fc qui se lie à des récepteurs fc? Avec un mode de liaison spécifique. Dans certains modes de réalisation, les molécules de liaison à un antigène bispécifiques selon la présente invention sont susceptibles d'inhiber la croissance de cellules bêta ou de tumeurs de mélanome exprimant cd20. Les anticorps bispécifiques selon la présente invention sont utiles pour le traitement de divers cancers ainsi que d'autres maladies et troubles associés au cd20.The present invention relates to bispecific antibodies that bind cd3 and tumor antigens and methods of their use. According to some embodiments, the bispecific antibodies according to the present invention exhibit reduced effector functions and possess a unique binding profile relative to fc? Receptors. The bispecific antibodies are engineered to efficiently induce T cell mediated death of tumor cells. In some embodiments, the present invention relates to bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds to human cd3, a second antigen-binding molecule that specifically binds to human cd20 , and an fc domain that binds to fc receptors? With a specific binding mode. In certain embodiments, the bispecific antigen-binding molecules according to the present invention are capable of inhibiting the growth of beta cells or melanoma tumors expressing cd20. The bispecific antibodies according to the present invention are useful for the treatment of various cancers as well as other diseases and disorders associated with cd20.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461955663P | 2014-03-19 | 2014-03-19 | |
PCT/US2015/021322 WO2015143079A1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for tumor treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39751B1 true MA39751B1 (en) | 2019-11-29 |
Family
ID=58699943
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA50374A MA50374B1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for the treatment of tumors |
MA39751A MA39751B1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for the treatment of tumors |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA50374A MA50374B1 (en) | 2014-03-19 | 2015-03-18 | Antibody compositions for the treatment of tumors |
Country Status (3)
Country | Link |
---|---|
AR (1) | AR099798A1 (en) |
HR (1) | HRP20210615T1 (en) |
MA (2) | MA50374B1 (en) |
-
2015
- 2015-03-18 MA MA50374A patent/MA50374B1/en unknown
- 2015-03-18 MA MA39751A patent/MA39751B1/en unknown
- 2015-03-19 AR ARP150100832A patent/AR099798A1/en unknown
-
2021
- 2021-04-19 HR HRP20210615TT patent/HRP20210615T1/en unknown
Also Published As
Publication number | Publication date |
---|---|
AR099798A1 (en) | 2016-08-17 |
MA50374A (en) | 2020-01-15 |
MA50374B1 (en) | 2021-06-30 |
HRP20210615T1 (en) | 2021-05-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42542B1 (en) | Molecules Binding to pd-1 and Corresponding Methods of Use | |
MA39313A1 (en) | Anti-egfrviii antibodies and their uses in the treatment of various cancers | |
MA35035B1 (en) | POLYPEPTIDE ANTIBODIES THAT ANTAGONIZE CD40 | |
MA40041A (en) | ANTI-GITR ANTIBODIES AND THEIR METHODS OF USE | |
MA40801A1 (en) | Anti-cd3 antibody, anti-cd123 antibody and bispecific antibodies binding specifically to cd3 and / or cd123 | |
MA42935B1 (en) | Optimized anti-cd3 bispecific antibodies and their uses | |
MA46708B1 (en) | Anti-pd1 antibodies and their uses | |
MA44312A (en) | ANTIBODIES AND THEIR METHODS OF USE | |
MA42622B1 (en) | LIAISONS IN TIGIT AND THEIR USES | |
MX2019013033A (en) | Stable formulations of anti-tigit antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof. | |
MX2020004410A (en) | Antibody compositions for tumor treatment. | |
CA2886433C (en) | Human monoclonal anti-pd-l1 antibodies and methods of use | |
TN2019000294A1 (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
MA38498B1 (en) | Anti-lag-3 binding proteins | |
EP3214096A3 (en) | Monospecific and bispecific anti-igf-1r and anti-erbb3 antibodies | |
MA33402B1 (en) | COMPOSITIONS AND METHODS FOR TARGETING COMPLEMENT C3B PROTEIN BY ANTIBODIES | |
MA33387B1 (en) | POLYPEPTIDES AND PROCESSING METHOD | |
MX2021005048A (en) | Anti-ctla4 antibodies, antibody fragments, their immunoconjugates and uses thereof. | |
ZA202107047B (en) | Heterodimeric antibodies that bind enpp3 and cd3 | |
EA202192146A1 (en) | ANTIBODIES FOR CLAUDIN 6 AND THEIR APPLICATION | |
ZA202206437B (en) | Claudin18.2 binding moieties and uses thereof | |
MX2023010499A (en) | Heterodimeric antibodies that bind cd3 and cldn6. | |
MA39751B1 (en) | Antibody compositions for the treatment of tumors | |
MA48751B1 (en) | ANTI-CD19 ANTIBODY TREATMENT PARADIGM AND VENETOCLAX COMBINATION TREATMENT | |
MX2022001882A (en) | 4-1bb and ox40 binding proteins and related compositions and methods, antibodies against 4-1bb, antibodies against ox40. |